Margaritis Avgeris

Prof. Margaritis Avgeris

Laboratory of Clinical Biochemistry – Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
+2
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MVMaria Vassilakopoulou
Maria Vassilakopoulou
Margaritis AvgerisMargaritis Avgeris
Margaritis Avgeris
VVVamsidhar Velcheti
Vamsidhar Velcheti
VKVassiliki Kotoula
Vassiliki Kotoula
TRTheodore Rampias
Theodore Rampias
APAmanda Psyrri
Amanda Psyrri
Purpose: Programmed death-ligand 1 (PD-L1; also known as CD274 or B7-H1) expression represents a mechanism of immune escape for cancer. Our purpose was to characterize tumor PD-L1 expression and associated T-cell infiltration in primary laryngeal squamous cell carcinomas (SCC).

4 July 2017 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
ASA. Strati
A. Strati
GKG. Koutsodontis
G. Koutsodontis
GPG. Papaxoinis
G. Papaxoinis
IAI. Angelidis
I. Angelidis
MZM. Zavridou
M. Zavridou
APAmanda Psyrri
Amanda Psyrri
Successful application of programmed death 1 (PD1) checkpoint inhibitors in the clinic may ultimately benefit from appropriate patient selection based upon predictive biomarkers. Molecular characterization of circulating tumor cells (CTC) is crucial for the investigation of molecular-targeted therapies while predictive biomarkers for response to PD1 checkpoint inhibitors are lacking. We sought to assess whether overexpression of PD-L1 in CTCs could be detected at baseline and at different timepoints during treatment in a prospective cohort of head and neck squamous cell carcinoma (HNSCC) patients and used to predict clinical outcome after treatment with curative intent. We developed a highly sensitive, specific and robust RT-qPCR assay for PD-L1 mRNA expression in EpCAM(+) CTCs. In a prospective cohort of 113 locally advanced HNSCC patients treated with curative intent we evaluated PD-L1 expression in the EpCAM(+) CTC fraction at baseline, after 2 cycles of induction chemotherapy (week 6) and at the end of concurrent chemoradiotherapy (week 15). PD-L1 overexpression was found in 24/94 (25.5%) patients at baseline, 8/34 (23.5%) after induction chemotherapy and 12/54 (22.2%) patients at the end of treatment. Patients with CTCs overexpressing PD-L1 at end of treatment had shorter progression-free survival (P = 0.001) and overall survival (P < 0.001). Multivariate analysis revealed that PD-L1 overexpression at end of treatment was independent prognostic factor for progression-free survival and overall survival. The absence of PD-L1 overexpression at the end of treatment was strongly associated with complete response with an odds ratio = 16.00 (95% CI = 2.76–92.72, P = 0.002). We demonstrate that detection of CTCs overexpressing PD-L1 is feasible and may provide important prognostic information in HNSCC. Our results suggest that adjuvant PD1 inhibitors deserve evaluation in HNSCC patients in whom PD-L1(+) CTCs are detected at the end of curative treatment.

7 September 2014 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TRTheodoros Rampias
Theodoros Rampias
PVParaskevi Vgenopoulou
Paraskevi Vgenopoulou
Margaritis AvgerisMargaritis Avgeris
Margaritis Avgeris
APAlexander Polyzos
Alexander Polyzos
KSKonstantinos Stravodimos
Konstantinos Stravodimos
AKApostolos Klinakis
Apostolos Klinakis

21 January 2019 in EMBO Reports
Verified
Journal Article
Open access
PDF file
Theodoros RampiasTheodoros Rampias
Theodoros Rampias
DKDimitrios Karagiannis
Dimitrios Karagiannis
Margaritis AvgerisMargaritis Avgeris
Margaritis Avgeris
APAlexander Polyzos
Alexander Polyzos
AKAntonis Kokkalis
Antonis Kokkalis
Apostolos KlinakisApostolos Klinakis
Apostolos Klinakis
Genome‐wide studies in tumor cells have indicated that chromatin‐modifying proteins are commonly mutated in human cancers. The lysine‐specific methyltransferase 2C (KMT2C/MLL3) is a putative tumor suppressor in several epithelia and in myeloid cells. Here, we show that downregulation of KMT2C in bladder cancer cells leads to extensive changes in the epigenetic status and the expression of DNA damage response and DNA repair genes. More specifically, cells with low KMT2C activity are deficient in homologous recombination‐mediated double‐strand break DNA repair. Consequently, these cells suffer from substantially higher endogenous DNA damage and genomic instability. Finally, these cells seem to rely heavily on PARP1/2 for DNA repair, and treatment with the PARP1/2 inhibitor olaparib leads to synthetic lethality, suggesting that cancer cells with low KMT2C expression are attractive targets for therapies with PARP1/2 inhibitors.

23 May 2013 in British Journal of Cancer
Verified
Journal Article
Open access
Margaritis AvgerisMargaritis Avgeris
Margaritis Avgeris
KSK Stravodimos
K Stravodimos
EFE G Fragoulis
E G Fragoulis
ASAndreas Scorilas
Andreas Scorilas
Background: Prostate cancer (PCa) is characterised by great heterogeneity of the disease progression rate. Tumours range from insignificant and not life threatening to high risk for relapse ones. Consequently, a large number of patients undergo unnecessary treatment. miR-145 is a well-documented tumour suppressor and its expression, which is regulated by the p53 pathway, has been found to be decreased in the majority of human malignancies. The aim of our study was to evaluate the clinical utility of miR-145 for the prognostication of PCa. Methods: Total RNA was isolated from 137 prostate tissue specimens obtained from 73 radical prostatectomy-treated PCa patients and 64 transurethral-or open prostatectomy-treated benign prostate hyperplasia (BPH) patients. Following polyadenylation and reverse transcription, miR-145 levels were determined by quantitative real-time PCR assay, using SNORD48 (RNU48) for normalisation purposes. Results: Downregulated miR-145 expression was found in PCa compared with BPH patients. The reduction of miR-145 expression in PCa was correlated with higher Gleason score, advanced clinical stage, larger tumour diameter and higher prostate-specific antigen (PSA) and follow-up PSA levels. In addition, higher risk for biochemical recurrence and significantly shorter disease-free survival (DFS) was found for the PCa patients expressing lower miR-145. Focusing on 'low- and intermediate-recurrence risk' PCa patients, miR-145 loss was revealed to be a reliable predictor of biochemical relapse and poor DFS independent from Gleason score, clinical stage, PSA and patients' age. Conclusion: The loss of the tumour-suppressor miR-145 increases the risk for disease progression and predicts the poor survival of PCa patients.

1 January 2021 in TrAC Trends in Analytical Chemistry
Verified
Journal Article
Open access
Nikiforos AlygizakisNikiforos Alygizakis
Nikiforos Alygizakis
AMAthina N. Markou
Athina N. Markou
Nikolaos RousisNikolaos Rousis
Nikolaos Rousis
AGAikaterini Galani
Aikaterini Galani
Margaritis AvgerisMargaritis Avgeris
Margaritis Avgeris
Nikolaos ThomaidisNikolaos Thomaidis
Nikolaos Thomaidis
In March 2020 the World Health Organization announced a pandemic outbreak. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative pathogen for the coronavirus disease-19 (COVID-19) pandemic. The authorities worldwide use clinical science to identify infected people, but this approach is not able to track all symptomatic and asymptomatic cases due to limited sampling capacity of the testing laboratories. This drawback is eliminated by the Wastewater-Based Epidemiology (WBE) approach. In this review, we summarized the peer-reviewed published literature (available as of September 28, 2020), in the field of WBE. The commonly used steps (sampling, storage, concentration, isolation, detection) of the analytical protocols were identified. The potential limitations of each stage of the protocols and good practices were discussed. Finally, new methods for the efficient detection of SARS-CoV-2 were proposed.